#USA #New York #Class Action #Levi Korsinsky #ADMA Biologics

Legal Action Looms for ADMA Biologics Investors

In a pivotal move within the realm of shareholder rights, Levi & Korsinsky, LLP has called attention to an impending class action lawsuit involving ADMA Biologics, Inc. (NASDAQ: ADMA). This announcement alerts investors who may have experienced financial loss due to alleged misconduct by senior executives during a defined class period. The lawsuit entails serious allegations including a purported scheme that misrepresented the financial performance of the company and instances of undisclosed transactions involving related parties.

Allegations Against Senior Executives

The lawsuit names three key executives: Adam S. Grossman, the CEO and President; Jerrold V. Grossman, Vice Chairman and co-founder; and Brad Tade, the former CFO. These individuals are accused of personally certifying financial statements that allegedly obscured a scheme to artificially inflate revenue via improper channel stuffing practices. This type of activity, if proven, could expose them to individual liability under federal securities regulations due to their duty to provide accurate financial disclosures.

Starting from August 9, 2024, until March 25, 2026, the misconduct allegedly concealed significant deficiencies in ADMA’s internal control measures and misrepresented the condition of its financial statements. Particularly, the complaint claims that ADMA's reported ASCENIV revenues grew from $92.6 million in 2023 to $362.5 million in 2025, even as an investigative report indicated that real revenue had actually decreased by 3% in the same year compared to inflated figures. The missed disclosures regarding related parties are serious violations that could impact investor confidence.

Legal Implications and Recovery Potential

The court has indicated that applications for lead plaintiff status must be submitted by August 10, 2026. A lead plaintiff will represent the collective interests of investors who have suffered losses, and choosing the right lead plaintiff can significantly influence the direction of the case. Individuals interested in joining the suit are encouraged to contact Levi & Korsinsky for an initial evaluation, as the firm operates on a contingency basis, meaning there are no upfront costs associated with joining the class action.

Levi & Korsinsky, recognized for their expertise in shareholder litigation, aims to ensure that investors recover their losses while holding corporate executives accountable for their actions. Joseph E. Levi, Esq., a partner at the firm, emphasized the importance of corporate accountability: “Corporate officers have a duty to ensure their companies' public statements are accurate and complete. When executives personally certify financial disclosures under Sarbanes-Oxley, they accept individual responsibility for those representations.”

What Investors Need to Know

Investors who purchased shares of ADMA Biologics during the defined class period but later sold at a loss can still be eligible for recovery. They should gather relevant brokerage statements that detail their purchase dates, quantities, and prices. Notably, participation in class actions does not require ongoing ownership of shares.

In terms of potential timeline, securities class actions typically take around two to four years to resolve from the initial filing to a final decision, an ongoing point of concern for investors hoping for swift resolution and recovery.

For investors of ADMA Biologics, the next steps are critical. Contacting Levi & Korsinsky can provide clarity and guidance on participating in this lawsuit and ensuring their investment rights are adequately represented and defended.

In summary, the unfolding developments concerning ADMA Biologics highlight the delicate interplay between corporate governance, investor protection, and legal accountability. As the situation continues to evolve, the repercussions for executives and the firm’s long-term viability remain to be seen.